A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Vamorolone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors ReveraGen BioPharma
- 10 May 2016 Status changed from recruiting to completed.
- 24 Feb 2015 New trial record
- 18 Feb 2015 Dosing of study participants has begun, according to a ReveraGen BioPharma media release.